Inês Leão
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Inês Leão has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Ana Joaquim
Department of Medical Oncology, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal
2 shared publications - Alberto Jorge Alves
Research Center in Sports Sciences, Health Sciences, and Human Development, University of Maia, Maia, Portugal
1 shared publication - Ana Campolargo
ONCOMOVE®-Associação de Investigação de Cuidados de Suporte Em Oncologia (AICSO), Vila Nova de Gaia, Portugal
1 shared publication - Andreia Capela
Serviço de Oncologia Médica. Centro Hospitalar Vila Nova de Gaia/Espinho. Vila Nova de Gaia; Associação de Investigação de Cuidados de Suporte em Oncologia. Vila Nova de Gaia
1 shared publication - Catarina Garcia
ONCOMOVE®—Associação de Investigação de Cuidados de Suporte em Oncologia (AICSO), 4410-406 Vila Nova de Gaia, Portugal
1 shared publication - David João
Department of Pathology, ULS Gaia e Espinho, Vila Nova de Gaia, Portugal
1 shared publication
Latest Publications
- Open Access
- 19 November 2025
- Published by Instituto Mexicano del Seguro Social in Revista Portuguesa Oncologia
- Vol. 8 (3)
Highlights from the 2025 American Society of Clinical Oncology Annual meeting: head-and-neck cancers
- 19 November 2025
- Published by Instituto Mexicano del Seguro Social in Revista Portuguesa Oncologia
- Vol. 8 (3)
Open AccessHighlights from the 2025 American Society of Clinical Oncology Annual meeting: head-and-neck cancers
- Open Access
Acute Impact of Cancer Treatment on Head and Neck Cancer Patients: FIT4TREATMENT
Head and neck cancer (HNC) treatment’s toxicities impact several health domains. Exercise training (ET) may be beneficial. This prospective observational study (NCT04996147) aimed to analyse the acute impact of HNC curative multimodal treatment on health-related quality of life (HRQoL), nutritional status, physical and cognitive functions, and ET preferences. Eighteen patients with stage III/IV HNC were evaluated at baseline (T0), and 10 patients were evaluated at the end of treatment (T1), 7 of them after radical chemoradiotherapy (rCRT). At T0, the majority referred a good HRQoL on the EORTC QLQ-C30 questionnaire (median score: 70.8), were moderately malnourished or at risk of malnutrition (78%), recognized the benefits of an ET program, and were willing to participate (78%). After rCRT, there was worsening in HRQoL (75 vs. 50 score, p = 0.014), dysphagia severity (Eating Assessment Tool: 7 vs. 31, p = 0.027; Functional Oral Intake Scale: 6 vs. 4, p = 0.041), handgrip strength (dominant: 40.9 vs. 35.8 kgf, p = 0.027; nondominant: 37.2 vs. 33.9 kgf, p = 0.043), and nutritional status (Patient-Generated Subjective Global Assessment: 7 vs. 18, p = 0.028). HNC patients subjected to radical treatment represent a vulnerable population that might benefit from multimodal supportive care strategies including an ET program.
Open AccessAcute Impact of Cancer Treatment on Head and Neck Cancer Patients: FIT4TREATMENT
Head and neck cancer (HNC) treatment’s toxicities impact several health domains. Exercise training (ET) may be beneficial. This prospective observational study (NCT04996147) aimed to analyse the acute impact of HNC curative multimodal treatment on health-related quality of life (HRQoL), nutritional status, physical and cognitive functions, and ET preferences. Eighteen patients with stage III/IV HNC were evaluated at baseline (T0), and 10 patients were evaluated at the end of treatment (T1), 7 of them after radical chemoradiotherapy (rCRT). At T0, the majority referred a good HRQoL on the EORTC QLQ-C30 questionnaire (median score: 70.8), were moderately malnourished or at risk of malnutrition (78%), recognized the benefits of an ET program, and were willing to participate (78%). After rCRT, there was worsening in HRQoL (75 vs. 50 score, p = 0.014), dysphagia severity (Eating Assessment Tool: 7 vs. 31, p = 0.027; Functional Oral Intake Scale: 6 vs. 4, p = 0.041), handgrip strength (dominant: 40.9 vs. 35.8 kgf, p = 0.027; nondominant: 37.2 vs. 33.9 kgf, p = 0.043), and nutritional status (Patient-Generated Subjective Global Assessment: 7 vs. 18, p = 0.028). HNC patients subjected to radical treatment represent a vulnerable population that might benefit from multimodal supportive care strategies including an ET program.
- Open Access
- 3 February 2022
- Published by Springer Nature in Cureus
- Vol. 14 (2) , e21881
Metaplastic Breast Carcinoma in a 37-Year-Old Female: A Case Report
Metaplastic breast carcinoma (MBC) is a rare and aggressive histologic subtype of cancer. Because of its rarity and heterogeneity, the management of these patients is challenging. Here, we present the case of a rapidly progressive MBC with mesenchymal differentiation in a 37-year-old female, treated with trimodal therapy consisting of neoadjuvant chemotherapy with paclitaxel and carboplatin, followed by dose-dense cyclophosphamide and doxorubicin (ddAC), modified radical left mastectomy, and adjuvant radiotherapy. Despite the need to anticipate the surgery after the first cycle of ddAC, because of a life-treating adverse event, there was a pathologic complete response. Nevertheless, 6.2 months after completing adjuvant radiotherapy, the patient had a recurrence on the central nervous system (CNS) (two lesions), which was managed with excisional biopsy and stereotactic body radiation therapy. The patient also started “complementary” chemotherapy with capecitabine. Still, 18 months after being diagnosed, she died due to CNS disease progression.
- 3 February 2022
- Published by Springer Nature in Cureus
- Vol. 14 (2) , e21881
Open AccessMetaplastic Breast Carcinoma in a 37-Year-Old Female: A Case Report
Metaplastic breast carcinoma (MBC) is a rare and aggressive histologic subtype of cancer. Because of its rarity and heterogeneity, the management of these patients is challenging. Here, we present the case of a rapidly progressive MBC with mesenchymal differentiation in a 37-year-old female, treated with trimodal therapy consisting of neoadjuvant chemotherapy with paclitaxel and carboplatin, followed by dose-dense cyclophosphamide and doxorubicin (ddAC), modified radical left mastectomy, and adjuvant radiotherapy. Despite the need to anticipate the surgery after the first cycle of ddAC, because of a life-treating adverse event, there was a pathologic complete response. Nevertheless, 6.2 months after completing adjuvant radiotherapy, the patient had a recurrence on the central nervous system (CNS) (two lesions), which was managed with excisional biopsy and stereotactic body radiation therapy. The patient also started “complementary” chemotherapy with capecitabine. Still, 18 months after being diagnosed, she died due to CNS disease progression.